This is a question often asked by Parkinson’s patients and families. The first thing to understand is that the root cause of Parkinson’s disease is a lack of dopamine in the brain, so the most direct and effective treatment is to replenish dopamine into the brain. This is what we do with methadopa, or restorative medicine. Any other new or effective drug is based on dopamine, and it is impossible to deviate from this principle. So it is clear that there will be no drugs that are better and more effective than methadopa or restorative, but there will be new drugs that will be developed that can play a supporting role. For example, dopamine receptor agonists, which improve the body’s sensitivity to dopamine. Monoamine oxidase-B inhibitors, COMT inhibitors (these two are slowing down the catabolism of dopamine and prolonging the action of dopamine in the brain). They increase the amount of dopamine in the brain through different pharmacological mechanisms, and practically no newer drug can be separated from this principle. There are currently six major classes of drugs for Parkinson’s disease: anticholinergics, amantadine, dopamine replacement therapy, dopamine receptor agonists, monoamine oxidase-B inhibitors, and COMT inhibitors. If we must say old and new, dopamine receptor agonists are new to the market.